Loading...
•
Mar 31, 2022
RAPT Q1 2022 Earnings Report
Reported financial results for the first quarter ended March 31, 2022 and maintained a strong cash position.
Key Takeaways
RAPT Therapeutics reported a net loss of $20.5 million for the first quarter of 2022, compared to a net loss of $16.5 million for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $173.0 million as of March 31, 2022.
Continued progress in programs in inflammatory diseases and oncology.
Reported biomarker data from Phase 1b clinical trial of RPT193 in atopic dermatitis.
Gearing up to initiate Phase 2b clinical trial in AD this quarter and Phase 2a trial in asthma in the second half of the year.
Continuing development of FLX475 in several oncology indications.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...